Tweet
Curr Drug Targets
. 2020 Dec 1.
doi: 10.2174/1389450121999201202110303. Online ahead of print.
Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance
Dinesh Singh Moirangthem 1 , Laishram Surbala 2
Affiliations
- PMID: 33267759
- DOI: 10.2174/1389450121999201202110303
Abstract
Background: Since its initial start on December 2019 at Wuhan, China, the coronavirus disease 2019 (COVID19) has been rapidly spreading and labelled as pandemic by World Health Organization. The rate of human to human transmission of COVID-19 is far higher than severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS). With no drugs or vaccines approved for the treatment of the disease, physicians have been using the pre-existing drugs to curb the disease. One potential anti-viral agent currently undergoing numerous clinical trial is remdesivir, a nucleotide analog that inhibits RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Objective: In this mini-review, we provide an overview of remdesivir's journey, mechanism of action, pharmacokinetics, used in patients with COVID-19 under compassionate use principle and clinical trials to understand the effect of remdesivir in the treatment of patients with COVID-19.
Conclusion: In this mini-review, we provide an overview of remdesivir's journey, mechanism of action, pharmacokinetics, used in patients with COVID-19 under compassionate use principle and clinical trials to understand the effect of remdesivir in the treatment of patients with COVID-19.
Keywords: COVID-19; GS-5734; SARS-CoV-2; coronavirus.; pandemic; remdesivir.